The Newlink Genetics Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of immunotherapy products to improve treatment options for cancer patients. The company’s products include biological and small molecule immunotherapy products. The company’s biological products are based on the company’s proprietary hyperacute immunotherapy technology, which aims to stimulate the human immune system. The company’s small-molecule products focus on breaking the cancer immune system’s tolerance by inhibiting the indoleamine -(2, 3) -plus dioxygenase pathway. The company believes its immunotherapy technology has the potential to produce multiple products for a wide range of cancer symptoms that can be treated alone or in combination with other therapies. The company was incorporated in Delaware on June 4, 1999 as the NewLink Genetics Corporation.
Q3 2019(9/30/19): Cash 98.53M. Loss 14.54M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 83，no change
Shares hold: 10356k shares. no change
shares% hold: 27.75%，no change